dc.contributor.author | AHMED, SALMA | |
dc.date.accessioned | 2020-09-26T07:39:42Z | |
dc.date.available | 2020-09-26T07:39:42Z | |
dc.date.issued | 2020-03-11 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/1969 | |
dc.description | Anemia occurring in patients with MM is multifactorial Several factors have been
implicated in the pathogenesis. Malignant plasma cells can supplant normal plasma
cells in the bone marrow This infiltration can lead to BM failure and anemia.
Multiple Myeloma is a clonal disorder of plasma cells that accounts for
approximately one percent of all cancers and ten percent of hematologic
malignancies. It is a disease of the elderly with a median age at diagnosis of 66 years
and less than 10% of cases occurring in patients younger than 50 years. Although new
therapeutics have improved the prognosis, myeloma remains incurable with a median
survival of 7–8 yrs It is 2–3 times more common in African Americans than in whites
and is slightly more common in men than women | en_US |
dc.description.abstract | Multiple myeloma (MM) accounts for 1% of all malignancies and more than 10% of
hematologic neoplasms. The disease is more common in elderly people, and blacks
are affected twice as frequently as whites. The cause of MM is unknown, although
significant progress has been made to have a better understanding of the pathogenesis.
The disease is very heterogeneous in terms of its extend complications sensitivity to
drugs and clinical course, and manifestations vary widely among patients. Anemia is a
common clinical manifestation in patients with MM | en_US |
dc.language.iso | en | en_US |
dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Hematological malignancy Associated with Anemia | en_US |
dc.type | Other | en_US |